Friday, 16 October 2026European Markets

PETRONOR E&P Stock Bullish By 21% In The Last 10 Sessions

Loading stream...

(VIANEWS) - Shares of PETRONOR E&P (Oslo Børs Benchmark Index_GI: PNOR.OL) rose by a staggering 21.18% in 10 sessions from kr0.66 to kr0.80 at 05:36 EST on Wednesday, after four consecutive sessions in a row of gains. Oslo Børs Benchmark Index_GI is rising 1.22% to kr1,209.83, following the last session's upward trend.

PETRONOR E&P's last close was kr0.80, 35.71% under its 52-week high of kr1.25.

About PETRONOR E&P

PetroNor E&P ASA operates as an independent oil and gas exploration and production company in West Africa. It holds exploration and production assets offshore West Africa, primarily the PNGF Sud licenses in Congo Brazzaville, the A4 license in The Gambia, the Sinapa (Block 2) and Esperança (Blocks 4A and 5A) licenses in GuineaBissau, the Rufisque Offshore Profond and Senegal Offshore Sud Profond in Senegal, and OML-113 in Nigeria. The company was founded in 2017 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, PETRONOR E&P has a trailing twelve months EPS of kr0.02.

PE Ratio

PETRONOR E&P has a trailing twelve months price to earnings ratio of 40.15. Meaning, the purchaser of the share is investing kr40.15 for every norwegian krone of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 41.65%.

Yearly Top and Bottom Value

PETRONOR E&P's stock is valued at kr0.80 at 05:36 EST, way below its 52-week high of kr1.25 and way higher than its 52-week low of kr0.66.

Revenue Growth

Year-on-year quarterly revenue growth grew by 86.1%, now sitting on 145.29M for the twelve trailing months.

Volume

Today's last reported volume for PETRONOR E&P is 2044950 which is 55.22% below its average volume of 3148610.

Moving Average

PETRONOR E&P's worth is higher than its 50-day moving average of kr0.78 and below its 200-day moving average of kr0.84.

More news about PETRONOR E&P (PNOR.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com